Tokyo, Japan

Mitsuo Sugiyama


Average Co-Inventor Count = 5.3

ph-index = 2

Forward Citations = 21(Granted Patents)


Location History:

  • Hiromachi, JP (1994 - 1995)
  • Tokyo, JP (1990 - 1997)

Company Filing History:


Years Active: 1990-1997

Loading Chart...
8 patents (USPTO):Explore Patents

Title: Mitsuo Sugiyama: A Pioneer in Pharmaceutical Innovations

Introduction

Mitsuo Sugiyama is a prominent inventor based in Tokyo, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the development of anti-ulcer and anti-allergic compounds. With a total of 8 patents to his name, Sugiyama's work has had a considerable impact on medical science.

Latest Patents

Among his latest patents, Sugiyama has developed anti-ulcer pyridyloxy derivatives, which have valuable anti-ulcer activity. These compounds are characterized by a complex formula that includes cyclic amino groups and various alkyl or aryl groups. Additionally, he has worked on 14B(R) isomers of novel tetracyclic compounds that exhibit anti-allergic properties. His innovative approach to these compounds showcases his expertise in medicinal chemistry.

Career Highlights

Sugiyama is currently associated with Sankyo Company, Limited, where he continues to push the boundaries of pharmaceutical research. His career is marked by a commitment to developing effective treatments for various health conditions, particularly those related to ulcers and allergies.

Collaborations

Throughout his career, Sugiyama has collaborated with notable colleagues, including Hiroshi Fukumi and Toshiaki Sakamoto. These partnerships have fostered a collaborative environment that enhances the innovation process and leads to groundbreaking discoveries.

Conclusion

Mitsuo Sugiyama's contributions to the pharmaceutical industry are noteworthy and reflect his dedication to improving health outcomes through innovative research. His patents and collaborations continue to influence the field, making him a significant figure in the world of inventions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…